Videos

Neurology News Network for the week ending June 1, 2019.

The MS neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed how leveraging real-world datasets can help reduce indication bias when comparing treatments for multiple sclerosis.

Despite high rates of depression in MS, picking up on signs that an individual may be at risk for suicide can be difficult. The staff neurologist at Cleveland Clinic’s Mellen Center discussed some of the red flags.

The MS neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health spoke about the factors that should be taken into account when making treatment decisions in MS, such as tolerability, affordability, and the desire to start family planning.

The podiatrist and CEO of Naboso Technology spoke about the potential of simple textured insoles to improve gait, posture, and balance in patients with MS experiencing ambulation issues.

The Director of Behavioral Medicine at the Mellen Center for MS Treatment and Research at the Cleveland Clinic spoke about how she approaches fatigue in MS from a behavioral standpoint.

The director of the Jefferson Headache Center at Jefferson University Hospital discussed the need for physicians to revisit how they treat patients with chronic migraine who have developed medication overuse headache.

Neurology News Network for the week ending May 25, 2019.

The chief medical officer and head of Research & Development at Ovid Therapeutics spoke about what prompted the development of this scale to measure improvement for patients with Fragile X syndrome, and possibly other conditions.

The director of the Pediatric Stroke Program at CHOP discussed the findings of a single-center study exploring the incidence of children presenting with acute arterial ischemic stroke who may have been eligible for mechanical thrombectomy.

Neurology News Network for the week ending May 18, 2019.

The associate professor of neurology at Mayo Clinic spoke about the findings of a population-based cohort study seeking to investigate the incidence of levodopa-induced dyskinesia in atypical parkinsonism.